Files in this item
Toxicity associated with tuberculosis chemotherapy in the REMoxTB study
Item metadata
dc.contributor.author | Tweed, Conor D. | |
dc.contributor.author | Crook, Angela M. | |
dc.contributor.author | Amukoye, Evans I. | |
dc.contributor.author | Dawson, Rodney | |
dc.contributor.author | Diacon, Andreas H. | |
dc.contributor.author | Hanekom, Madeline | |
dc.contributor.author | McHugh, Timothy D. | |
dc.contributor.author | Mendel, Carl M. | |
dc.contributor.author | Meredith, Sarah K. | |
dc.contributor.author | Murphy, Michael E. | |
dc.contributor.author | Murthy, Saraswathi E. | |
dc.contributor.author | Nunn, Andrew J. | |
dc.contributor.author | Phillips, Patrick P. J. | |
dc.contributor.author | Singh, Kasha P. | |
dc.contributor.author | Spigelman, Melvin | |
dc.contributor.author | Wills, Genevieve H. | |
dc.contributor.author | Gillespie, Stephen H. | |
dc.date.accessioned | 2018-07-12T16:30:10Z | |
dc.date.available | 2018-07-12T16:30:10Z | |
dc.date.issued | 2018-07-11 | |
dc.identifier.citation | Tweed , C D , Crook , A M , Amukoye , E I , Dawson , R , Diacon , A H , Hanekom , M , McHugh , T D , Mendel , C M , Meredith , S K , Murphy , M E , Murthy , S E , Nunn , A J , Phillips , P P J , Singh , K P , Spigelman , M , Wills , G H & Gillespie , S H 2018 , ' Toxicity associated with tuberculosis chemotherapy in the REMoxTB study ' , BMC Infectious Diseases , vol. 18 , 317 . https://doi.org/10.1186/s12879-018-3230-6 | en |
dc.identifier.issn | 1471-2334 | |
dc.identifier.other | PURE: 254689688 | |
dc.identifier.other | PURE UUID: 8a6c9f25-228f-4535-9dc7-eaaeb5dc2a81 | |
dc.identifier.other | RIS: urn:757744015F086D32E56E1BD8417539C3 | |
dc.identifier.other | RIS: Tweed2018 | |
dc.identifier.other | Scopus: 85049843197 | |
dc.identifier.other | ORCID: /0000-0001-6537-7712/work/46569222 | |
dc.identifier.other | WOS: 000438284500001 | |
dc.identifier.uri | https://hdl.handle.net/10023/15335 | |
dc.description | Supported by the Global Alliance for TB Drug Development with support from the Bill and Melinda Gates Foundation, the European and Developing Countries Clinical Trials Partnership (grant IP.2007.32011.011), U.S. Agency for International Development, U.K. Department for International Development, Directorate General for International Cooperation of the Netherlands, Irish Aid, Australia Department of Foreign Affairs and Trade, and National Institutes of Health, AIDS Clinical Trials Group and by grants from the National Institute of Allergy and Infectious Diseases (NIAID) (UM1AI068634, UM1 AI068636, and UM1AI106701) and by NIAID grants to the University of KwaZulu Natal, South Africa, AIDS Clinical Trials Group (ACTG) site 31,422 (1U01AI069469); to the Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, South Africa, ACTG site 12,301 (1U01AI069453); and to the Durban International Clinical Trials Unit, South Africa, ACTG site 11,201 (1U01AI069426); Bayer Healthcare for the donation of moxifloxacin; and Sanofi for the donation of rifampin. | en |
dc.description.abstract | Background: The incidence and severity of tuberculosis chemotherapy toxicity is poorly characterised. We used data available from patients in the REMoxTB trial to provide an assessment of the risks associated with the standard regimen and two experimental regimens containing moxifloxacin. Methods: All grade 3 & 4 adverse events (AEs) and their relationship to treatment for patients who had taken at least one dose of therapy in the REMoxTB clinical trial were recorded. Univariable logistic regression was used to test the relationship of baseline characteristics to the incidence of grade 3 & 4 AEs and significant characteristics (p < 0.10) were incorporated into a multivariable model. The timing of AEs during therapy was analysed in standard therapy and the experimental arms. Logistic regression was used to investigate the relationship between AEs (total and related-only) and microbiological cure on treatment. Results: In the standard therapy arm 57 (8.9%) of 639 patients experienced ≥1 related AEs with 80 of the total 113 related events (70.8%) occurring in the intensive phase of treatment. Both four-month experimental arms (“isoniazid arm” with moxifloxacin substituted for ethambutol & “ethambutol arm” with moxifloxacin substituted for isoniazid) had a lower total of related grade 3 & 4 AEs than standard therapy (63 & 65 vs 113 AEs). Female gender (adjOR 1.97, 95% CI 0.91–1.83) and HIV-positive status (adjOR 3.33, 95% CI 1.55–7.14) were significantly associated with experiencing ≥1 related AE (p < 0.05) on standard therapy. The most common adverse events on standard therapy related to hepatobiliary, musculoskeletal and metabolic disorders. Patients who experienced ≥1 related AE were more likely to fail treatment or relapse (adjOR 3.11, 95% CI 1.59–6.10, p < 0.001). Conclusions: Most AEs considered related to standard therapy occurred in the intensive phase of treatment with female patients and HIV-positive patients demonstrating a significantly higher risk of AEs during treatment. Almost a tenth of standard therapy patients had a significant side effect, whereas both experimental arms recorded a lower incidence of toxicity. That patients with one or more AE are more likely to fail treatment suggests that treatment outcomes could be improved by identifying such patients through targeted monitoring. | |
dc.format.extent | 11 | |
dc.language.iso | eng | |
dc.relation.ispartof | BMC Infectious Diseases | en |
dc.rights | © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. | en |
dc.subject | Tuberculosis | en |
dc.subject | Toxicity | en |
dc.subject | Clinical trials | en |
dc.subject | Adverse events | en |
dc.subject | RA0421 Public health. Hygiene. Preventive Medicine | en |
dc.subject | E-DAS | en |
dc.subject | SDG 3 - Good Health and Well-being | en |
dc.subject.lcc | RA0421 | en |
dc.title | Toxicity associated with tuberculosis chemotherapy in the REMoxTB study | en |
dc.type | Journal article | en |
dc.description.version | Publisher PDF | en |
dc.contributor.institution | University of St Andrews. School of Medicine | en |
dc.contributor.institution | University of St Andrews. Infection and Global Health Division | en |
dc.contributor.institution | University of St Andrews. Global Health Implementation Group | en |
dc.contributor.institution | University of St Andrews. Gillespie Group | en |
dc.contributor.institution | University of St Andrews. Biomedical Sciences Research Complex | en |
dc.contributor.institution | University of St Andrews. Infection Group | en |
dc.identifier.doi | https://doi.org/10.1186/s12879-018-3230-6 | |
dc.description.status | Peer reviewed | en |
This item appears in the following Collection(s)
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.